Intravenous immune globulin in myasthenia gravis.
Myasthenia gravis (MG) is an autoimmune disease of neuromuscular transmission associated with the presence of anti-acetylcholine receptor antibodies (anti-AChR Ab). Current treatment of MG includes anti-cholinesterase drugs, thymectomy, corticosteroids, immunosuppressants and plasma exchange (PE). The use of intravenous immune globulin (IVIG) in MG was proposed 10 years ago. Published results of IVIG treatment are discussed and the need for a controlled study is emphasized.
Service de Réanimation Médicale, Hôpital Raymond Poincaré, Garches, France.
P
P
Gajdos
D001323:Autoantibodies / Q000097:blood; D018680:Cholinergic Antagonists; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D009157:Myasthenia Gravis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D010951:Plasma Exchange; D011950:Receptors, Cholinergic / Q000276:immunology
D001323:Autoantibodies; D018680:Cholinergic Antagonists; D016756:Immunoglobulins, Intravenous; D011950:Receptors, Cholinergic